The integration of the triple angiogenic biomarkers ANG‐2/Tie‐2/VEGF‐C within the tumor microenvironment, combined with the regulatory influence of hormonal receptors, merits further investigation as a potential biomarker panel for identifying lymphatic anomalies and VI positivity in breast cancer patients. This evidence concerns the gene ANGPT2 and breast cancer.